|Preeclampsia (or pregnancy related hypertension) is the most common complication to occur during pregnancy. It accounts for over $2.18 billion of U.S. health care expenditures in the first 12 months after birth. Of the 131 million pregnancies per year (4 million in the United States), approximately 10 percent are complicated by hypertension, leading to 3 million premature births. New insights suggest compromised blood flow through the kidneys plays a fundamental role in the development of preeclampsia. Researchers at Purdue University are refining a wearable biometric intended to screen for compromised kidney blood flow in 100 percent of pregnant women with the goal of predicting and preventing preeclampsia.
Symptoms of preeclampsia can include high blood pressure, protein in the urine, swelling, and seizures. After the 20th week of pregnancy, the mass of the pregnant abdomen is well known to affect kidney blood flow, especially when a woman lies on her back. In women with a vulnerable anatomy, this compromised blood flow leads to high blood pressure. Previously published work has shown that an acute elevation in blood pressure associated with a pregnant woman shifting from her side to her back predicts approximately 90% of preeclampsia. The procedure is known as the supine pressure test (SPT). Furthermore, when detected early, rest in a therapeutic position, on one's side for example, has been shown to prevent preeclampsia.
Purdue University researchers have developed a wearable biometric intended to both predict preeclampsia and better manage those women identified to be at risk. The technology couples a blood pressure measuring device with a body position sensor to ensure meticulous execution of the SPT. The device transmits via smartphone the changes in blood pressure and calculated predictive risk to a remote medical location. Sequential testing is intended to optimize test sensitivity. For those women identified to be at risk, the wearable device is also programmed to monitor a pregnant woman's resting position and communicate with her as needed to optimize position. The goal is to better predict and prevent preeclampsia and to allow expecting mothers to monitor their own health without frequent travel to a clinic.
-Predicts, manages, or prevents preeclampsia
-Testing performed in the comfort of home
-Results transmit to remote medical professionals
-Early detection and prevention of preeclampsia
-Reduce the number of premature births resulting from preeclampsia
-Allow expecting mothers to monitor their own blood pressure without traveling to a clinic for frequent monitoring
-Similar application available for those with obesity-related hypertension, since physiology has been shown to be similar. U.S. hypertensive population is 76 million.
Feb 13, 2020
Jan 21, 2020
Aug 29, 2018
Sep 5, 2017
Purdue Office of Technology Commercialization
The Convergence Center
101 Foundry Drive, Suite 2500
West Lafayette, IN 47906
Phone: (765) 588-3475
Fax: (765) 463-3486